RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects
07 March 2012
RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.
Rusnano, US fund to invest $760 mln in pharma venture
06 March 2012
Russian state technology firm Rusnano is teaming up with a U.S. venture fund to invest around $760 million in a number of U.S. healthcare and pharmaceuticals firms, establish a manufacturing facility in Russia and bring new drugs to the Russian market.
Domain partners with RusNano on $760M biotech investment plan
06 March 2012
The Russians are back. After capturing the attention of the nanobio crowd with a few hefty investments in the U.S., RusNano is now partnering with Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies.
Rusnano Teams Up With U.S. Fund Domain to Invest in Life Science
06 March 2012
Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
03 November 2024
Russia to conduct an experiment on monitoring dietary supplement manufacturers
03 December 2024
Sustainable analytical approach devised for complex drug formulation
03 December 2024
Branches of Russian medical universities are planned to be opened in Kazakhstan
02 December 2024
AI and automation to drive “substantial progress” in pharmaceutical analytical testing
02 December 2024